Salix Company Profile

What is the competitive landscape for SALIX

SALIX has eighteen approved drugs.

There are sixty-one US patents protecting SALIX drugs.

There are five hundred and fifty-five patent family members on SALIX drugs in fifty-five countries and ninety-seven supplementary protection certificates in twelve countries.

Summary for Salix

International Patents:	555
US Patents:	61
Tradenames:	15
Ingredients:	13
NDAs:	18
Patent Litigation for Salix:	See patent lawsuits for Salix
PTAB Cases with Salix as patent owner:	See PTAB cases with Salix as patent owner

Drugs and US Patents for Salix

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Salix Pharms	DIURIL	chlorothiazide	SUSPENSION;ORAL	011870-001	Approved Prior to Jan 1, 1982		RX	Yes	Yes
Salix	FENOGLIDE	fenofibrate	TABLET;ORAL	022118-001	Aug 10, 2007		DISCN	Yes	No
Salix	RELISTOR	methylnaltrexone bromide	TABLET;ORAL	208271-001	Jul 19, 2016		RX	Yes	Yes	8,524,276		Y
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745-001	Jan 19, 2017		RX	Yes	Yes	9,610,321

Expired US Patents for Salix

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Salix	UCERIS	budesonide	TABLET, EXTENDED RELEASE;ORAL	203634-001	Jan 14, 2013	RE43799
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010	7,902,206
Salix	ZEGERID	omeprazole; sodium bicarbonate	FOR SUSPENSION;ORAL	021636-002	Dec 21, 2004	6,489,346
Salix	ZEGERID	omeprazole; sodium bicarbonate	FOR SUSPENSION;ORAL	021636-002	Dec 21, 2004	5,840,737

Paragraph IV (Patent) Challenges for SALIX drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	40 mg and 120 mg		2010-03-17
	Injection	8 mg/0.4 mL		2015-09-08
	For Oral Solution	100 g, 7.5 g, 2.691 g, 1.015 g, 5.9 g and 4.7 g per pouch		2007-11-27
	Tablets	1.102 g and 0.398 g		2008-04-09
	Tablets	200 mg		2019-01-28
	Extended-release Capsules	0.375 g		2012-04-03
	Powder for Oral Suspension	40 mg/1680 mg per packet		2007-08-24
	For Oral Solution	140 g, 5.2 g, 2.2.g, 48.11 g, 9g and 7.54 g per pouch		2018-12-06
	Injection	12 mg/0.6 mL		2015-07-22
	Tablets	150 mg		2016-09-06
	Orally Disintegrating Tablets	5 mg and 10 mg		2010-08-24
	Tablets	550 mg		2015-12-18
	Extended-release Tablets	9 mg		2013-03-11
	Capsules	20 mg/1100 mg and 40 mg/1100 mg		2007-04-30
	Powder for Oral Suspension	20mg/1680mg per packet		2007-11-13

International Patents for Salix Drugs

Country	Patent Number	Estimated Expiration
Brazil	PI0920465
Hong Kong	1092150
South Africa	201408706
World Intellectual Property Organization (WIPO)	2010040021

Supplementary Protection Certificates for Salix Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1499331	13C0055	France		PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220
2203431	15C0013	France		PRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119
2435024	301102	Netherlands		PRODUCT NAME: COMBINATIE VAN FORMOTEROL (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN), GLYCOPYRROLAAT (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN) EN BUDESONIDE (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN); REGISTRATION NO/DATE: EU/1/20/1498 20201210
0480717	SPC/GB98/025	United Kingdom		PRODUCT NAME: MONTELUKAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY MONTELUKAST SODIUM; REGISTERED: FI 12766 19970825; FI 12767 19970825; UK 00025/0357 19980115; UK 00025/0358 19980115

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Salix
• Salix Pharms

Pharmaceutical Competitive Landscape Analysis: Salix – Market Position, Strengths & Strategic Insights

In the dynamic world of pharmaceuticals, Salix Pharmaceuticals stands out as a major player in the gastrointestinal (GI) market. This comprehensive analysis delves into Salix's market position, strengths, and strategic insights, providing valuable information for industry professionals and investors alike.

Company Overview

Salix Pharmaceuticals, founded in 1989, has grown to become the largest gastroenterology-focused pharmaceutical company in the world[1]. Based in Bridgewater, New Jersey, Salix specializes in developing and marketing prescription drugs and medical devices for various gastrointestinal disorders[1][2].

Market Position

Dominant Force in Gastroenterology

Salix has established itself as a leader in the gastroenterology pharmaceutical market. Its focus on GI disorders has allowed the company to build a strong reputation and expertise in this niche area[1][4].

Revenue and Growth

As of the latest available data, Salix's estimated annual revenue stands at $277.2 million[5]. The company has shown impressive growth, with a 14% increase in employee count last year[5].

Key Products

Salix's product portfolio includes several successful treatments for GI disorders. One of its standout products is Xifaxan, which treats irritable bowel syndrome and chronic liver disease. Xifaxan alone generates approximately $1 billion in annual revenue[2].

Strengths and Competitive Advantages

Specialized Focus

Salix's dedication to gastroenterology gives it a competitive edge. This specialization allows for deeper understanding and innovation in GI treatments[4].

Strong Product Pipeline

The company continually invests in research and development, maintaining a robust pipeline of potential new treatments[7].

Strategic Acquisitions

Salix has a history of strategic acquisitions that have expanded its product portfolio and market reach. Notable acquisitions include InKine Pharmaceutical Company, Oceana Therapeutics, and Santarus[1].

Global Partnerships

Salix has engaged in strategic global agreements, such as the partnership with Photocure for Lumacan, a photodynamic colorectal diagnostic tool[1].

Strategic Insights

Focus on Education

"One of the company's major points of growth is through the education of primary care physicians in both the state and around the country on irritable bowel syndrome and other gastrointestinal disorders." - Mark McKenna, Salix Senior Vice President and General Manager[2]

This focus on educating healthcare professionals about GI disorders helps Salix build strong relationships with prescribers and position itself as a thought leader in the field.

Expansion of Sales Force

Salix has significantly increased its sales force, scaling up by nearly 40% in recent years[7]. This expansion allows for greater market penetration and improved relationships with healthcare providers.

Research and Development

Continuous innovation is key to Salix's strategy. The company invests heavily in R&D to develop new treatments and improve existing ones[7].

Market Access Strategies

Salix employs sophisticated market access strategies to ensure its products are available and affordable to patients. This includes working closely with insurance providers and healthcare systems[4].

Competitive Landscape

Major Competitors

While Salix leads in the GI-focused pharmaceutical space, it faces competition from larger pharmaceutical companies with GI divisions. Competitors may include companies like AbbVie (Allergan), Takeda, and Johnson & Johnson.

Competitive Analysis Techniques

To maintain its competitive edge, Salix likely employs various competitive analysis techniques:

1. SWOT Analysis: Evaluating strengths, weaknesses, opportunities, and threats in the GI pharmaceutical market[3].

2. Porter's Five Forces: Analyzing competitive intensity and market attractiveness[3].

3. Benchmarking: Comparing key performance indicators with competitors, such as R&D spend and time-to-market for new products[3].

4. Social Media Monitoring: Tracking competitors' digital presence and marketing strategies[3].

Future Outlook

Market Trends

The GI pharmaceutical market is expected to grow significantly in the coming years, driven by factors such as an aging population and increasing prevalence of GI disorders.

Potential Challenges

Salix may face challenges such as patent expirations, increasing competition from generics, and the need for continuous innovation to maintain market leadership.

Opportunities for Growth

Potential areas for growth include:

1. Expanding into international markets
2. Developing treatments for rare GI disorders
3. Leveraging AI and machine learning in drug discovery
4. Focusing on patient-centric metrics and outcomes

Impact of Valeant Acquisition

In 2015, Valeant Pharmaceuticals (now Bausch Health) acquired Salix for $14.5 billion[1]. This acquisition has provided Salix with additional resources and a broader platform for growth.

Key Takeaways

1. Salix Pharmaceuticals is the world's largest gastroenterology-focused pharmaceutical company.
2. The company's specialized focus, strong product pipeline, and strategic acquisitions are key strengths.
3. Salix's flagship product, Xifaxan, generates approximately $1 billion in annual revenue.
4. The company emphasizes educating healthcare professionals about GI disorders as a growth strategy.
5. Salix faces competition from larger pharmaceutical companies but maintains its leadership in the GI space.
6. Future growth opportunities include international expansion and leveraging new technologies in drug discovery.

FAQs

1. Q: What is Salix Pharmaceuticals' main focus? A: Salix Pharmaceuticals specializes in developing and marketing treatments for gastrointestinal disorders.

2. Q: Who are Salix Pharmaceuticals' main competitors? A: While Salix leads in the GI-focused space, it competes with larger pharmaceutical companies that have GI divisions, such as AbbVie (Allergan), Takeda, and Johnson & Johnson.

3. Q: What is Salix's most successful product? A: Xifaxan, which treats irritable bowel syndrome and chronic liver disease, is Salix's best-selling drug, generating approximately $1 billion in annual revenue.

4. Q: How has the Valeant (now Bausch Health) acquisition affected Salix? A: The acquisition has provided Salix with additional resources and a broader platform for growth, contributing to its market leadership.

5. Q: What strategies is Salix using to maintain its competitive edge? A: Salix focuses on educating healthcare professionals, expanding its sales force, investing in R&D, and employing sophisticated market access strategies to maintain its competitive advantage.

Sources cited: [1] https://en.wikipedia.org/wiki/Salix_Pharmaceuticals [2] https://njbiz.com/salix-pharmaceuticals-focuses-on-gastrointestinal-market-for-opportunities/ [3] https://www.drugpatentwatch.com/blog/the-importance-of-pharmaceutical-competitor-analysis/ [4] https://www.acep.org/apc/attendees-bios/partners/salix-pharmaceuticals-profile [5] https://growjo.com/company/Salix_Pharmaceuticals [7] https://www.salix.com/about-us/history/